• NAT1–ENO1–Lactate Axis in Colorectal Cancer

  2026-09-14

  A 2026 MedComm study defines NAT1 as a metabolic–immune regulator in colorectal cancer, showing that NAT1-dependent acetylation of ENO1 limits lactate production and downstream PD-L1 stabilization. The work connects tumor glycolysis with TRAF6 signaling and checkpoint therapy response, while providing a framework for testing pathway-specific metabolic interventions.

• HNF4A-AS1, Lipid Metabolism, and Sorafenib Resistance

  2026-09-14

  A 2024 Theranostics study identifies the liver-enriched lncRNA HNF4A-AS1 as a suppressor of sorafenib resistance in hepatocellular carcinoma by regulating ferroptosis-related lipid metabolism. Its mechanistic model links HNF4A-AS1 to METTL3-dependent m6A modification of DECR1 mRNA, polyunsaturated fatty acid abundance, and therapeutic response, providing a framework for studying metabolic determinants of drug resistance.

• Fumagillin Workflows for Angiogenesis Research

  2026-09-13

  Fumagillin is a methionine aminopeptidase-2 inhibitor that supports mechanism-driven studies of endothelial cell proliferation and tumor-associated angiogenesis. This guide translates reference-backed antiparasitic testing into practical assay design while clearly separating validated evidence from cross-domain research recommendations.

• Oleanolic Acid, FXR, and Cholestatic Liver Injury

  2026-09-12

  The reference study identifies impaired FXR-regulated bile acid efflux and hepatocyte tight-junction disruption as linked mechanisms of oleanolic acid-induced cholestatic liver injury. Its combined in vivo, in vitro, LC–MS/MS, imaging, and pharmacological-intervention strategy provides a useful framework for evaluating FXR-dependent bile acid transport and barrier integrity.

• CHIR-99021 for Stem Cell and Vascular Assays

  2026-09-11

  CHIR-99021 (CT99021) converts GSK-3 inhibition into a practical lever for pluripotency, lineage differentiation, and pathway-perturbation experiments. This guide connects reproducible dosing and handling with vascular organoid workflows inspired by recent high-glucose research, while clearly separating established uses from testable extensions.

• GSK 2837808A: LDHA Inhibition Workflow

  2026-09-11

  GSK 2837808A provides a focused way to test LDHA-driven lactate production, glucose use, and tumor-cell signaling without treating glycolysis as one undifferentiated process. This workflow connects validated hepatocellular carcinoma evidence with carefully bounded, hypothesis-generating applications in colorectal cancer metabolism research.

• Ionic-Liquid Assembly of Coil-Bottlebrush Diblocks

  2026-09-10

  This 2024 Macromolecules study examines how coil-block-bottlebrush diblock copolymers self-assemble in alkylimidazolium ionic liquids with systematically varied alkyl-chain lengths. Its central finding is that, despite changes in solvent selectivity, the resulting lyotropic phase behavior depends only weakly on ionic-liquid identity, broadening the design space for polymer networks and related nanostructured materials.

• GSK J4 HCl: Practical JMJD3 Inhibition Workflows

  2026-09-10

  GSK J4 HCl connects intracellular H3K27 demethylase inhibition with practical assays for inflammation, chromatin regulation, and cancer biology. This guide emphasizes dose interpretation, locus-specific validation, cell-based controls, and troubleshooting rather than treating one endpoint as proof of mechanism.

• L-Glutathione Reduced in GOT1 Redox Assays

  2026-09-09

  Use L-Glutathione Reduced as a practical redox perturbation, GST elution reagent, and mechanistic control in oxidative-stress and pancreatic cancer workflows. This guide connects fresh-solution handling with the GOT1-centered findings of a pancreatic ductal adenocarcinoma study, while separating product-supported facts from assay starting recommendations.

• Angiotensin III: A Receptor-Aware RAAS Tool

  2026-09-09

  Angiotensin III is more than a downstream RAAS metabolite: its cleavage state, receptor profile, and assay context can change experimental interpretation. This guide connects A1043 product specifications with a 2025 spike–receptor binding study to support better cardiovascular, neuroendocrine, and cross-domain assay design.

• circRNA–FXR/TLR4 Signaling in NiONP Fibrosis

  2026-09-08

  A 2025 Toxics study links hsa_circ_0001944 with FXR/TLR4 signaling, ferroptosis, and nickel oxide nanoparticle-induced collagen deposition in LX-2 hepatic stellate cells. Its combined pharmacological and genetic design suggests a regulatory route from circular RNA loss to FXR suppression, TLR4 elevation, altered ferroptosis, and fibrotic activation, while retaining important limits for translation beyond cell and animal models.

• 4-MUG Assays for Lysosomal Enzyme Research

  2026-09-08

  Use 4-MUG to convert β-glucosidase and β-glucocerebrosidase activity into a sensitive, tunable fluorescence readout. This workflow connects routine enzyme kinetics with GBA1-deficient cell models and functional evaluation of emerging mRNA-LNP strategies for Gaucher disease.

• p53 Inhibition Meets Neuroinflammatory Pain Biology

  2026-09-07

  An evidence-led perspective on using Cyclic Pifithrin-α hydrobromide to test whether p53-dependent stress responses modify the Ca2+-CGRP/SP–Piezo2 circuitry underlying trigeminal mechanical allodynia, while preserving a clear boundary between established evidence and translational hypotheses.

• GSK126 EZH2 Inhibitor: Practical Workflows

  2026-09-07

  Use GSK126 to connect PRC2-dependent gene silencing with measurable chromatin, viability, inflammatory, and autophagy phenotypes. This workflow-oriented guide covers oncology applications, a cautious neuroinflammation bridge, dose design, and troubleshooting for reproducible EZH2 experiments.

• Foretinib (GSK1363089): From Kinase Map to Translation

  2026-09-05

  Foretinib (GSK1363089) offers a translational framework for connecting multikinase biology with more rigorous cancer drug-response measurements. This thought-leadership article examines how Met and VEGFR pathway inhibition, endpoint selection, motility assays, and in vivo modeling can strengthen preclinical decisions.

7803 records 1/521 page Next 12345 下5页 Last page